LED Medical Announces US Distribution Agreement with Benco Dental

LED Medical Diagnostics Inc. ("LED Medical" or the "Company") (TSX VENTURE:LMD)(LEDIF)(LME.F) is pleased to announce that its wholly-owned subsidiary, LED Dental Inc. ("LED Dental"), has entered into a non-exclusive partnership with Benco Dental ("Benco") for the distribution of the Company's VELscope® Vx Enhanced Oral Assessment System and product line within the United States market.

"We are pleased to partner with Benco for distribution in the United States," stated Dr. David Gane, CEO for LED Medical. "Benco currently serves more than 35,000 customers across the country and maintains an excellent reputation in the dental industry. We are excited about the opportunity to work together, maximizing the significant sales potential for the VELscope® Vx product line through its extensive network."

NeuroMetrix to Partner with Omron Medical Devices for Distribution of NC-stat DPNCheck in China

NeuroMetrix, Inc. (NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, announced that it had entered into an agreement with Omron Medical Devices, a subsidiary of Omron Healthcare China, to be the exclusive distributor for NC-stat^® DPNCheck^® in China. Earlier this year NeuroMetrix and Omron Healthcare Co. Ltd. announced a partnership for the exclusive distribution of NC-stat DPNCheck in Japan.

NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test for early detection of diabetic peripheral neuropathy (DPN), which affects over half of people with diabetes. DPN causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.

Covidien Announces Definitive Agreement to Acquire Given Imaging

    Advances Covidien strategy to more comprehensively address key specialties and procedures globally
    Adds Given Imaging’s broad suite of minimally invasive gastrointestinal diagnostic and monitoring solutions
    Accelerates development of world-class gastrointestinal portfolio focused on serving patient from diagnosis to treatment
    Accretive to earnings per share beginning in fiscal 2015

Covidien plc (COV) and Given Imaging Ltd. (GIVN) today announced a definitive agreement under which Covidien will acquire all of the outstanding shares of Given Imaging for $30.00 per share in cash, for a total of approximately $860 million, net of cash and investments acquired. This transaction provides Covidien additional scale and scope to serve the multibillion dollar global gastrointestinal (GI) market and supports the Company’s strategy to comprehensively address key global specialties and procedures.

Oculus Innovative Sciences Receives FDA Clearance for Microcyn(R) Scar Management HydroGel

Oculus U.S Dermatology Partner, Quinnova Pharmaceuticals, Targeting U.S. Launch in Q2 2014

U.S. Double-Blind, Randomized Study for Scar Management Establishes Strong Foundation for International Approval

Oculus Innovative Sciences, Inc. (OCLS), a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 27 countries, today announced that it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's new Microcyn(R) Scar Management HydroGel.